Clinical trial
Once Daily 3TC, Efavirenz and ddI for HIV Infection
NCT00214435 · 407 Doctors, Other · Unknown status
Key facts
| NCT number | NCT00214435 |
|---|---|
| Title | Once Daily 3TC, Efavirenz and ddI for HIV Infection |
| Official title | A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily |
| Lead sponsor | 407 Doctors, Other |
| Collaborators | Bristol-Myers Squibb Industry Merck Sharp & Dohme LLC |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infection, AIDS |
| Intervention type | Drug |
| Interventions | once daily minimum 3-drug regimen of anti-retroviral medications |
| Enrollment | 120 |
| Start date | May 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 25, 2005 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: